WO2004071573A3 - Hypoxia induced mitogenic factor - Google Patents

Hypoxia induced mitogenic factor Download PDF

Info

Publication number
WO2004071573A3
WO2004071573A3 PCT/US2004/003875 US2004003875W WO2004071573A3 WO 2004071573 A3 WO2004071573 A3 WO 2004071573A3 US 2004003875 W US2004003875 W US 2004003875W WO 2004071573 A3 WO2004071573 A3 WO 2004071573A3
Authority
WO
WIPO (PCT)
Prior art keywords
himf
hypoxia
relmα
fizz1
rpsm
Prior art date
Application number
PCT/US2004/003875
Other languages
French (fr)
Other versions
WO2004071573A2 (en
Inventor
Roger Johns
Xingwu Teng
Dechun Li
Original Assignee
Univ Johns Hopkins
Roger Johns
Xingwu Teng
Dechun Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Roger Johns, Xingwu Teng, Dechun Li filed Critical Univ Johns Hopkins
Priority to EP04709501A priority Critical patent/EP1596926A2/en
Priority to US10/543,658 priority patent/US7671037B2/en
Publication of WO2004071573A2 publication Critical patent/WO2004071573A2/en
Publication of WO2004071573A3 publication Critical patent/WO2004071573A3/en
Priority to US12/698,696 priority patent/US8080533B2/en
Priority to US13/211,923 priority patent/US8414891B2/en
Priority to US13/334,387 priority patent/US8329177B2/en
Priority to US13/793,354 priority patent/US20130243782A1/en
Priority to US14/482,398 priority patent/US20150004172A1/en
Priority to US15/273,757 priority patent/US9878005B2/en
Priority to US15/865,629 priority patent/US20190262422A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)

Abstract

We found that FIZZ1/RELMα is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELMα was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELMα protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (P13K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
PCT/US2004/003875 2003-02-07 2004-02-09 Hypoxia induced mitogenic factor WO2004071573A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP04709501A EP1596926A2 (en) 2003-02-07 2004-02-09 Hypoxia induced mitogenic factor
US10/543,658 US7671037B2 (en) 2003-02-07 2004-02-09 Hypoxia induced mitogenic factor
US12/698,696 US8080533B2 (en) 2003-02-07 2010-02-02 Hypoxia induced mitogenic factor
US13/211,923 US8414891B2 (en) 2003-02-07 2011-08-17 Method for treating pulmonary hypertension
US13/334,387 US8329177B2 (en) 2003-02-07 2011-12-22 Method of treating hypertrophic cardiomyopathy
US13/793,354 US20130243782A1 (en) 2003-02-07 2013-03-11 Hypoxia-induced mitogenic factor
US14/482,398 US20150004172A1 (en) 2003-02-07 2014-09-10 Hypoxia-induced mitogenic factor
US15/273,757 US9878005B2 (en) 2003-02-07 2016-09-23 Method of promoting wound healing with hyodxia-induced mitogenic factor
US15/865,629 US20190262422A1 (en) 2003-02-07 2018-01-09 Hypoxia-induced mitogenic factor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44559403P 2003-02-07 2003-02-07
US60/445,594 2003-02-07

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10543658 A-371-Of-International 2004-02-09
US10/543,658 A-371-Of-International US7671037B2 (en) 2003-02-07 2004-02-09 Hypoxia induced mitogenic factor
US12/698,696 Division US8080533B2 (en) 2003-02-07 2010-02-02 Hypoxia induced mitogenic factor

Publications (2)

Publication Number Publication Date
WO2004071573A2 WO2004071573A2 (en) 2004-08-26
WO2004071573A3 true WO2004071573A3 (en) 2008-07-24

Family

ID=32869386

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/003875 WO2004071573A2 (en) 2003-02-07 2004-02-09 Hypoxia induced mitogenic factor

Country Status (3)

Country Link
US (8) US7671037B2 (en)
EP (1) EP1596926A2 (en)
WO (1) WO2004071573A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1596926A2 (en) * 2003-02-07 2005-11-23 The Johns Hopkins University Hypoxia induced mitogenic factor
US8343491B2 (en) * 2006-12-18 2013-01-01 The Johns Hopkins University Anti-HIMF antibodies to treat lung diseases
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP2708601A1 (en) * 2012-09-14 2014-03-19 ETH Zürich Treatment of heart disease through modulation of hypoxia induced eRNA activity
CN113249297A (en) 2014-05-28 2021-08-13 儿童医院医疗中心 Methods and systems for converting precursor cells to stomach tissue via directed differentiation
US11584916B2 (en) 2014-10-17 2023-02-21 Children's Hospital Medical Center Method of making in vivo human small intestine organoids from pluripotent stem cells
EP3452578B1 (en) 2016-05-05 2022-08-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
NZ753873A (en) 2016-12-05 2023-01-27 Children’S Hospital Medical Center Colonic organoids and methods of making and using same
CN107884585B (en) * 2017-10-24 2019-09-27 深圳大学 The protein detection kit of the mitogenic factor of hypoxia inducible and its application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058061A1 (en) * 1997-06-19 1998-12-23 Schering Corporation Mammalian genes; related reagents
WO1999055868A2 (en) * 1998-04-24 1999-11-04 Genentech, Inc. Fizz proteins
WO2000004923A1 (en) * 1998-07-23 2000-02-03 Smithkline Beecham Corporation Scrp-5: secreted cysteine rich protein-5
WO2000053760A2 (en) * 1999-03-12 2000-09-14 Genentech, Inc. Method of preventing the death of retinal neurons and treating ocular diseases
US20020142982A1 (en) * 1999-09-02 2002-10-03 Timothy Hla Method for regulating angiogenesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6411A (en) * 1849-05-01 Chtjkn-dasher
AU2001258836A1 (en) * 2000-05-26 2001-12-03 Kensuke Egashira Preventives and remedies for pulmonary hypertension
EP1596926A2 (en) * 2003-02-07 2005-11-23 The Johns Hopkins University Hypoxia induced mitogenic factor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058061A1 (en) * 1997-06-19 1998-12-23 Schering Corporation Mammalian genes; related reagents
WO1999055868A2 (en) * 1998-04-24 1999-11-04 Genentech, Inc. Fizz proteins
WO2000004923A1 (en) * 1998-07-23 2000-02-03 Smithkline Beecham Corporation Scrp-5: secreted cysteine rich protein-5
WO2000053760A2 (en) * 1999-03-12 2000-09-14 Genentech, Inc. Method of preventing the death of retinal neurons and treating ocular diseases
US20020142982A1 (en) * 1999-09-02 2002-10-03 Timothy Hla Method for regulating angiogenesis

Also Published As

Publication number Publication date
US8329177B2 (en) 2012-12-11
US8414891B2 (en) 2013-04-09
US20170065674A1 (en) 2017-03-09
US20130243782A1 (en) 2013-09-19
EP1596926A2 (en) 2005-11-23
US20120039839A1 (en) 2012-02-16
US20110008349A1 (en) 2011-01-13
US20150004172A1 (en) 2015-01-01
WO2004071573A2 (en) 2004-08-26
US8080533B2 (en) 2011-12-20
US20190262422A1 (en) 2019-08-29
US20120141489A1 (en) 2012-06-07
US20060229241A1 (en) 2006-10-12
US9878005B2 (en) 2018-01-30
US7671037B2 (en) 2010-03-02

Similar Documents

Publication Publication Date Title
Yoshida et al. Mechanisms of cachexia in chronic disease states
Borkham-Kamphorst et al. Pro-fibrogenic potential of PDGF-D in liver fibrosis
D'Alto et al. Bosentan–sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology
Kolka et al. The barrier within: endothelial transport of hormones
DeCicco et al. Serum and liver concentrations of tumor necrosis factor α and interleukin-1β following administration of carbon tetrachloride to male rats
Durand et al. Angiotensin-(1-7) and low-dose angiotensin II infusion reverse salt-induced endothelial dysfunction via different mechanisms in rat middle cerebral arteries
WO2011060206A3 (en) Material and methods for treating or preventing her-3 associated diseases
Ng et al. Indoxyl sulfate downregulates expression of Mas receptor via OAT3/AhR/Stat3 pathway in proximal tubular cells
Cozzolino et al. Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease: a hypothesis
Guazzi et al. Endothelial dysfunction and lung capillary injury in cardiovascular diseases
WO2007047969A3 (en) Methods of decreasing vascular calcification using il-1 inhibitors
WO2006018024A3 (en) Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
WO2004071573A3 (en) Hypoxia induced mitogenic factor
Andres et al. Discordant signaling and autophagy response to fasting in hearts of obese mice: Implications for ischemia tolerance
Kitada et al. Mechanism of activation of mechanistic target of rapamycin complex 1 by methionine
MX2014002471A (en) Synergistic combinations of pi3k- and mek-inhibitors.
Rossi et al. Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: Role in disease conditions: a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension
Leong et al. Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats
Dao et al. Nitric oxide up-regulates endothelial expression of angiotensin II type 2 receptors
Cohen-Segev et al. Cardiac and renal distribution of ACE and ACE-2 in rats with heart failure
Chiang et al. N-acetylcysteine attenuates ventilator-induced lung injury in an isolated and perfused rat lung model
Wu et al. Mechanisms of the beneficial effect of NHE1 inhibitor in traumatic hemorrhage: inhibition of inflammatory pathways
Klinger et al. Natriuretic peptides differentially attenuate thrombin-induced barrier dysfunction in pulmonary microvascular endothelial cells
Kaufmann et al. Effect of marathon and ultra‐marathon on inflammation and iron homeostasis
WO2009108706A3 (en) Methods for inhibiting six 1 and eya proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004709501

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2004709501

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006229241

Country of ref document: US

Ref document number: 10543658

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10543658

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2004709501

Country of ref document: EP